Opinion|Videos|August 7, 2024

EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

Author(s)Lawrence Karsh, MD, FACS, Stephen J. Freedland, MD, Terence Friedlander, MD

Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

Episodes in this series

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 1 Prostate Cancer Treatment: The Evolving Therapeutic Landscape

Stephen Freedland, MD, an expert on prostate cancer

EP. 2 The Heterogeneity of Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 3 The Role of ADT in Localized or Locally Advanced Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 4 EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 5 Treatment Considerations in Nonmetastatic CSPC

Terence Friedlander, MD, an expert on prostate cancer

EP. 6 Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 7 Treatment Options in Castration-Resistant Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 8 The Relationship Between Prostate Cancer and Cardiovascular Disease

Stephen Freedland, MD, an expert on prostate cancer

EP. 9 Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 10 ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

ByLorelei A. Mucci, ScD, MPH

September 11th 2026

Doublet or triplet? Urologists weighs in on mCSPC options

ByUrology Times staff

September 10th 2026

Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD

ByMartin Schoen, MD, PhD,Hannah Clarke

September 10th 2026

App-based intervention aims to increase PSA screening among Black men

ByHannah Clarke

September 9th 2026

The critical role of advocacy in urologic oncology

ByRuchika Talwar, MD,Lan Anh Galloway, MD

September 9th 2026

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

AI-generated profiles impersonate female urologists to market ED products online

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Doublet or triplet? Urologists weighs in on mCSPC options

Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA

Prior auth, step therapy, and consolidation pressure: Independent urology's challenge